So many unknowns about carfilzomib in #MMsm around the 🌎 - help tell us what you do! Link below for any oncologist treating myeloma: 12 q's, <3 min. Thank you! redcap.link/carfilzomib cc Gurbakhash Kaur Vincent Rajkumar Georgia McCaughan Nikita Mehra Adam Sperling BoWangMD and more!

Irene Ghobrial presenting data and rationale of early use of immunotherapy in patients with HR-SMM at the IMS Immune Therapies Meeting Myeloma Society Dana-Farber #mmsm

Congrats Alex Silver. Very nice work.

Congratulations to my former Broadie and DFCI colleagues for their induction as 2024 ⁦AACR⁩ Fellows #AACR24 ⁦Broad Institute⁩ ⁦Dana-Farber⁩ . Well deserved.

IFYKYK … two of the true OGs of #BMT catching the eclipse and looking good doing it ⁦⁦Dana-Farber⁩ ⁦Rizwan Romee⁩ ⁦Mahasweta Gooptu⁩ ⁦Corey Cutler⁩

MRD as an official endpoint for accelerated approval ODAC votes 12-0 great work by all congratulations!!

Getting MRD as an endpoint was a great partnership between academia and industry and patient organization. A model to follow. Patients are three winner. Vincent Rajkumar #@NoopurRajeMD #myelomasociety

We are looking for a couple of Research Technicians to join us in the Fischer Lab! If you enjoy biochemistry/chem bio and are interested in working in a great team exploring degrader induced interactions and degradation reach out or apply: careers.dana-farber.org/job/research-t… Please RT!

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients w... sciencedirect.com/science/articl… Sharing our experience with a Quad in #mmsm @betsyodonnellmd Andrew Yee, MD Mass General Cancer Center

Come join our group! Please share with those interested. careers.dana-farber.org/job/scientist-…

Plasma cell neoplasm retreat ⁦Dana-Farber⁩ with the giants of myeloma. Amazing day. #mmsm

New IMS high risk definition for multiple myeloma presented by Prof Corre COMy . Fantastic effort by co-operative groups to redefine risk. Clearly an evolving area.

Newly open application for the Advanced Fellowship in Leukemia Dana-Farber. Led by Marlise R. Luskin MD, MSCE Please share.

A potential disaster for patients with cancer if such a major budget cut happens. Cancer clinicians and researchers need to speak up in all ways possible on behalf of our patients.

Am certainly sad to see him leave but sounds like an amazing opportunity. Congrats Jens!

Endogenous polymerization of BTB domains: Our initial hypothesis was that this would lead to protein degradation, but instead, polymerization led to enhanced chromatin binding at homotypic clusters, causing transcriptional repression. Great story spearheaded by amazing Park Team!

Excited to share our paper in Nature Biotechnology. We've developed a CAR-Enhancer (CAR-E) that enhances the activity and persistence of CAR T-cells. These memory CAR T-cells can re-expand months later. Here's a brief summary: go.nature.com/3SuUgj3

Laurie H. Glimcher, MD, Dana-Farber’s transformative President and CEO, announced today that she will step down on October 1, 2024, and will assume the title of President Emerita. Benjamin Levine Ebert, MD, PhD, chair of Department of Medical Oncology and a world-renowned

📢 excited to announce that our clinical research on EASIX & post-CAR-T complications & outcomes has been published in Journal for ImmunoTherapy of Cancer This study offers further insights into potential biomarkers for better risk stratification & toxicity management. #mmsm

Cannot recommend this lab highly enough.